Compare Capri Holdings Ltd (CPRI) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs McKesson Corporation — how do they compare? Capri Holdings Ltd trades at $14.69 (market cap $1.67B), while McKesson Corporation trades at $930 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 64.9× Capri Holdings Ltd's market cap, and McKesson Corporation pays a 0.4% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and McKesson Corporation for 74 Days on average.
| CPRI | MCK | |
|---|---|---|
Market Cap | $1.67B | $108.46B |
Volume | 3,722,279 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $995.69 |
52-Week Low | $12.71 | $725.17 |
Typical Hold Time | 41 Days | 74 Days |
Enterprise Value | $2.95B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $1.18 billion in 2025, though recent quarters have consistently beaten EPS estimates. Revenue has declined from $5.7 billion in 2022 to $4.44 billion in 2025, but management expects second-half growth driven by brand revitalization efforts at Michael Kors and Jimmy Choo.
The stock presents a mixed outlook with a low P/S ratio of 0.5 and a consensus price target of $20.57 offering potential upside. However, significant risks include persistent revenue declines, high debt levels, and competitive pressures in the luxury sector. Analyst sentiment is divided with 44% buy ratings versus 52% hold, reflecting uncertainty about the turnaround timeline.
McKesson Corporation (MCK) trades at $910.33, down 1.23% today, but maintains strong analyst support with 80.65% buy ratings and a $956.43 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a major distribution agreement extension with CVS Health through 2032. Revenue growth has accelerated from $264B in 2022 to $359B in 2025, though net margins remain thin at 1.12%.
MCK presents a compelling growth story with consistent earnings outperformance and strategic partnerships driving long-term visibility. However, investors face risks from margin compression, drug pricing pressures, and high leverage with negative shareholder equity. The current valuation at 24.42x P/E appears reasonable given the company's market leadership and oncology growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
